AF after TMVR: anticoagulation wins the duel against antiplatelets

The antithrombotic dilemma post-TMVR in cases of atrial fibrillation

Transcatheter mitral valve repair (TMVR/TEER), particularly via the edge-to-edge technique, has established itself as a major therapeutic alternative for patients suffering from severe mitral regurgitation at high surgical risk. However, post-procedural antithrombotic management remains complex: the prevalence of atrial fibrillation (AF) in these patients is massive, estimated between 56% and 75%. These individuals face a dual risk: thromboembolic, exacerbated by atrial stasis and endothelial lesions due to the device, and haemorrhagic, often linked to advanced age and multiple comorbidities. Currently, no standardised protocol exists, leaving clinicians to navigate between the empirical use of antiplatelet agents (APA) and oral anticoagulation (OAC).

Objectives and hypotheses of the meta-analysis

This systematic review with network meta-analysis aims to synthesize data from four multicenter observational cohorts (n = 2,098 patients) to quantify the efficacy and safety of different antithrombotic regimens. The study specifically analyzes the impact of oral anticoagulation (including DOACs and VKAs such as warfarin and phenprocoumon) versus antiplatelet agents (aspirin or clopidogrel, alone or in combination) on three major criteria: ischemic stroke, major bleeding, and all-cause mortality. The central hypothesis is to identify whether an OAC strategy provides a superior net clinical benefit compared to APT in this high-risk population.

Methodology: a network meta-analysis on observational data

The authors conducted a systematic review and network meta-analysis based on searches performed up to August 25, 2025. The objective was to compare the efficacy and safety of antithrombotic treatments in patients with atrial fibrillation (AF) following transcatheter edge-to-edge mitral valve repair (TEER/MitraClip).

The total population includes 2,098 patients from four multicentric cohorts (Mentias, Hohmann, Waechter, and Schipper studies). Inclusion criteria targeted adults (≥18 years) with a documented history of AF requiring post-procedure anticoagulation.

Therapeutic protocols have been harmonized into two main groups:

• Oral anticoagulation (OAC): including direct oral anticoagulants (DOACs: rivaroxaban, apixaban, edoxaban, dabigatran) and vitamin K antagonists (VKAs: warfarin or phenprocoumon).
• Antiplatelet therapy (APT): aspirin and/or clopidogrel, administered as single antiplatelet therapy (SAPT) or dual antiplatelet therapy (DAPT).

Statistical analysis used pairwise and network random-effects models to calculate odds ratios (OR) with a 95% confidence interval. However, the quality of evidence is limited: assessment via RoB 2.0 and ROBINS-I reveals a risk of bias judged as "serious" for three out of four studies (Hohmann, Waechter, Schipper), mainly due to the non-randomised nature of treatment allocation and potential selection biases.

Data analysis: A clear advantage for anticoagulation

The synthesis compiles results from 2,098 patients (according to the abstract) distributed across four multicentre observational cohorts. The authors report a consistent trend: OAC strategies present a superior safety and efficacy profile compared to APT.

• Hemorrhagic risk: OAC strategies are associated with a reduction in the risk of major bleeding compared to APT. Notably, in the study by Hohmann et al., the OAC group presented half as many hemorrhagic events (8/540) as the APT group (16/458).
• All-cause mortality: Data consistently favor OACs, and more specifically direct oral anticoagulants (DOACs). In Mentias et al., the death rate is 14% with DOACs compared to 19% with Warfarin.
• Stroke Prevention: OAC (notably phenprocoumon in European cohorts) shows better efficacy in preventing ischemic events compared to APT.

The meta-analysis highlights, however, a heterogeneity of results for DOACs depending on the comparator used (phenprocoumon in Europe vs. warfarin in the United States). The network geometry remains limited, with most contrasts based on only one or two studies.

Discussion: The OAC, a paradoxically safer choice?

This meta-analysis, involving 2,098 patients from four multicentre cohorts, challenges certain empirical practices. While the use of antiplatelet therapy (APT) after TMVR is common, the compiled data suggest that oral anticoagulation (OAC) offers a better clinical compromise for patients with atrial fibrillation. Notably, OAC does not only reduce the risk of ischaemic stroke; it also appears to be associated with a reduction in bleeding risk and all-cause mortality compared to APT.

The figures from the study by Mentias et al. (2022) are particularly telling: under DOAC, a mortality rate of 69/491 is observed compared to 131/687 under Warfarin, accompanied by a decrease in major bleeding (54/491 vs 103/687). This trend is corroborated by the study by Hohmann et al., where the OAC group presented fewer bleeding events (8/540) than the APT group (16/458). Clinically, this suggests that thrombotic protection is not achieved at the cost of increased vascular fragility, quite the contrary.

Methodological limits and interpretative caution

The scope of these results must, however, be tempered by the quality of the evidence. With the exception of Mentias et al. (moderate risk due to propensity score adjustment), the included studies (Schipper, Waechter, Hohmann) present a serious risk of bias related to their observational design and the lack of randomization. The heterogeneity of bleeding definitions (ISTH, BARC, TIMI) and the geographical variability of comparators (phenprocoumon in Europe vs. warfarin in the United States) limit the absolute generalizability of the conclusions.

Conclusion

Although this systematic review highlights a potential superiority of OAC strategies, particularly DOACs, over antiplatelet agents, the need for randomized clinical trials remains urgent to validate these observations in this frail and elderly population.

Summary of results

This meta-analysis of four multicentre cohorts (n = 2,098) demonstrates that oral anticoagulation (OAC), whether DOACs or VKAs, presents a superior safety profile compared to antiplatelet agents (APA) after TMVR/TEER in patients with atrial fibrillation. The results indicate a significant reduction in bleeding risk, better prevention of ischaemic strokes (particularly with phenprocoumon), and consistently lower all-cause mortality under OAC compared to APA.

In concrete terms, for the practitioner:

• Prioritize OAC alone: For your AF patients undergoing TEER, oral anticoagulation should be the gold standard strategy, surpassing antiplatelets (aspirin/clopidogrel) for the combined reduction of thrombotic and hemorrhagic risk.
• Avoid the dogma of post-procedure APAs: Contrary to empirical practices, APAs alone do not provide sufficient protection against ischemic stroke in this population and paradoxically increase the risk of major bleeding.
• Individualize based on local data: Although DOACs are generally favorable for survival, their comparative effectiveness may vary depending on the type of VKA used (e.g., phenprocoumon vs warfarin); rigorous clinical monitoring remains essential due to the observational nature of current data.

Technical Lexicon

TMVR / TEER: Transcatheter Mitral Valve Repair / Transcatheter Edge-to-Edge Repair. Percutaneous mitral repair techniques, notably via the MitraClip device.

OAC (Oral Anticoagulation): Oral anticoagulation including vitamin K antagonists (VKA) and direct oral anticoagulants (DOAC).

Phenprocoumon: Vitamin K antagonist (VKA) mainly used in Germany and the Netherlands, featured in the Schipper and Hohmann cohorts.

Network meta-analysis: Statistical technique allowing for the indirect comparison of multiple treatments that have not been the subject of direct (head-to-head) comparisons in the source studies.

Inverse probability weighting: Statistical adjustment method used to correct selection bias in observational studies by weighting individuals according to their probability of receiving a treatment.

Propensity score matching: Statistical technique aimed at reducing the effect of confounding variables by matching patients with similar clinical characteristics but different treatments.

Information intended for healthcare professionals. This content may contain errors or truncated summaries. We recommend always verifying with the original source article. Delynov disclaims all responsibility regarding the use of this information. This document is not intended for patients or the general public.